Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans

Vaccine

Volumn 19, Issue 13-14, 2001, Pages 1732-1737

  Treanor, John J ^a   Wilkinson, Bethanie E ^b   Masseoud, Feda ^c   Hu Primmer, Jean ^c   Battaglia, Rosalyn ^a   O'Brien, Diane ^a   Wolff, Mark ^d   Rabinovich, Gina ^e   Blackwelder, William ^e   Katz, Jacqueline M ^c  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Protein Sciences Corp   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d EMMES CORPORATION   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Avian influenza; Clinical trials; Vaccines

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MALAISE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS; INFLUENZA VACCINES; KINETICS; NEUTRALIZATION TESTS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035825607     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00395-9     Document Type: Article

References (18)

1. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness
2. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus
3. Human influenza A H5N1 related to a highly pathogenic avian influenza virus
4. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-98
5. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong
6. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997
7. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts
8. Risk of influenza A (H5N1) infection among health-care workers exposed to patients with influenza A (H5N1), Hong Kong
9. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults
10. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults
11. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults
12. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays
13. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model
14. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines
15. Replication of avian influenza A viruses in mammals
16. Potential for transmission of avian influenza viruses to pigs
17. Evaluation of two doses of either subunit- or MF-59 adjuvanted subunit influenza Duck/Singapore Q/F119-3/97 (H5N3) vaccine in healthy adults
18. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans